IDO1 and melanoma: Epacadostat (INCB024360) was the first IDO1 inhibitor to advance into a phase III clinical trial (ECHO-301/KEYNOTE-252) after showing promising efficacy in advanced melanoma patients when combined with α-PD-1 antibodies in two nonrandomized, uncontrolled phase II trials (343, 344).